Page 1 | Search Results | Molecular Cancer Therapeutics | American Association for Cancer Research

1-4 of 4

Sort by

Sort Order Select

Journal Articles

Modeling Targeted Inhibition of MEK and PI3 Kinase in Human Pancreatic Cancer

Melissa R. Junttila, Vidusha Devasthali, Jason H. Cheng, Joseph Castillo, Ciara Metcalfe, Anne C. Clermont, Douglas Den Otter, Emily Chan, Hani Bou-Reslan, Tim Cao, William Forrest, Michelle A. Nannini, Dorothy French, Richard Carano, Mark Merchant, Klaus P. Hoeflich, Mallika Singh

Mol Cancer Ther (2015) 14 (1): 40–47.

https://doi.org/10.1158/1535-7163.MCT-14-0030

Published: 13 January 2015

View articletitled, Modeling Targeted Inhibition of MEK and PI3 Kinase in Human Pancreatic Cancer

Includes: Supplementary data

Journal Articles

Abstract B190: GDC-0068 is a novel and selective Akt inhibitor that enhances the efficacy of FOLFOX in primary gastric cancer models.

Ellen Ingalla, Rebecca Hong, Heidi Savage, Elizabeth Punnoose, Sandra Rost, Hartmut Koeppen, Deepak Sampath, Michelle A. Nannini

Mol Cancer Ther (2013) 12 (11_Supplement): B190.

https://doi.org/10.1158/1535-7163.TARG-13-B190

Published: 01 November 2013

View articletitled, Abstract B190: GDC-0068 is a novel and selective Akt inhibitor that enhances the efficacy of FOLFOX in primary gastric cancer models.

Journal Articles

Bcl-2/Bcl-x_L Inhibition Increases the Efficacy of MEK Inhibition Alone and in Combination with PI3 Kinase Inhibition in Lung and Pancreatic Tumor Models

Nguyen Tan, Maureen Wong, Michelle A. Nannini, Rebecca Hong, Leslie B. Lee, Stephen Price, Karen Williams, Pierre Pascal Savy, Peng Yue, Deepak Sampath, Jeffrey Settleman, Wayne J. Fairbrother, Lisa D. Belmont

Mol Cancer Ther (2013) 12 (6): 853–864.

https://doi.org/10.1158/1535-7163.MCT-12-0949

Published: 09 June 2013

View articletitled, Bcl-2/Bcl-xL Inhibition Increases the Efficacy of MEK Inhibition Alone and in Combination with PI3 Kinase Inhibition in Lung and Pancreatic Tumor Models

Includes: Supplementary data

Journal Articles

Contribution of individual targets to the antitumor efficacy of the multitargeted receptor tyrosine kinase inhibitor SU11248

Olga Potapova, A. Douglas Laird, Michelle A. Nannini, Angela Barone, Guangmin Li, Katherine G. Moss, Julie M. Cherrington, Dirk B. Mendel

Mol Cancer Ther (2006) 5 (5): 1280–1289.

https://doi.org/10.1158/1535-7163.MCT-03-0156

Published: 26 May 2006

View articletitled, Contribution of individual targets to the antitumor efficacy of the multitargeted receptor tyrosine kinase inhibitor SU11248

Update search

NARROW

Format

Subjects

Journal

Article Type

Issue Section

Date

Availability

Modeling Targeted Inhibition of MEK and PI3 Kinase in Human Pancreatic Cancer

Abstract B190: GDC-0068 is a novel and selective Akt inhibitor that enhances the efficacy of FOLFOX in primary gastric cancer models.

Bcl-2/Bcl-x_L Inhibition Increases the Efficacy of MEK Inhibition Alone and in Combination with PI3 Kinase Inhibition in Lung and Pancreatic Tumor Models

Contribution of individual targets to the antitumor efficacy of the multitargeted receptor tyrosine kinase inhibitor SU11248

Email alerts

AACR Journals

Update search

Modeling Targeted Inhibition of MEK and PI3 Kinase in Human Pancreatic Cancer

Abstract B190: GDC-0068 is a novel and selective Akt inhibitor that enhances the efficacy of FOLFOX in primary gastric cancer models.

Bcl-2/Bcl-xL Inhibition Increases the Efficacy of MEK Inhibition Alone and in Combination with PI3 Kinase Inhibition in Lung and Pancreatic Tumor Models

Contribution of individual targets to the antitumor efficacy of the multitargeted receptor tyrosine kinase inhibitor SU11248

Email alerts

AACR Journals

This Feature Is Available To Subscribers Only

Bcl-2/Bcl-x_L Inhibition Increases the Efficacy of MEK Inhibition Alone and in Combination with PI3 Kinase Inhibition in Lung and Pancreatic Tumor Models